Sixty-six adults with refractory acute lymphocytic leukemia received salvage therapy with the 'hyper-CVAD' regimen, consisting of eight courses of alternating intensive chemotherapy with growth factor support, followed by oral maintenance chemotherapy. Their outcome was compared with 63 prognostically similar historical control patients treated with high-dose Ara-C plus mitoxantrone with or without GM-CSF. Overall, the complete response rates were similar in the treatment and control groups (29 of 66 (44%) vs 24 of 63 (38%)). There were more patients in the current study with primary resistant disease (10 of 66 (15%) vs one of 63 (2%), P = 0.006), and conversely fewer patients with secondary resistance (19 of 66 (29%) vs 28 of 63 (44%), P = 0.06). Recovery of granulocyte counts above 500/l was significantly faster in the current study when compared to high-dose Ara-C-treated patients who were given GM-CSF (20 vs 25 days, P = 0.04). Survival was prolonged in the hyper-CVAD-treated patients, with most of the benefit seen in first salvage patients (42 vs 20 weeks, P = 0.016). When only first salvage patients were considered, there was a significant difference in disease-free survival in favor of hyper-CVAD (52 vs 20 weeks, P = 0.008). The hyper-CVAD regimen is a more effective and less toxic salvage regimen for relapsed acute lymphocytic leukemia than high-dose Ara-C-based regimens.
Introduction
The treatment of acute lymphoblastic leukemia in adults is modeled after pediatric regimens in which the expected cure rate is 50-75%.
1,2 While a complete remission can be obtained in 60-80% of previously untreated adults, only about 20-30% of those patients will be cured of their disease. 3, 4 Prognostic variables that predict patient outcome include age, performance status, degree of leukocytosis, and leukemia karyotype and immunophenotype. [3] [4] [5] Once a patient relapses or fails to achieve a complete remission, salvage chemotherapy regimens have been reported to have reinduction rates of 20-60%, but, nevertheless, median CR remission duration averages only 3.4 months. 6 Over a period of 44 months, 66 patients at our institution were given salvage chemotherapy with the 'hyper-CVAD' regimen, a dose-intensive regimen patterned after the childhood Burkitt ALL therapy designed by Murphy et al. 7 We called the regimen 'hyper-CVAD' after the acronym for the initial induction combination. 8 Our findings are summarized in this report. 
Materials and methods

Study population
Sixty-six patients with relapsed ALL were treated between April 1992 and November 1995. Informed consent for treatment was obtained from each patient according to institutional guidelines. Criteria for entry were: (1) the presence of 30% or more blasts in the bone marrow or more than 10 000 circulating blasts/l in the peripheral blood; (2) a performance status of 0 to 2 on Zubrod scale; and (3) normal renal and hepatic functions. Workup at presentation included history and physical examination; documentation of the extent of disease; complete blood counts (CBC), platelet count, and differential; SMA12 with liver and renal function studies; bone marrow aspiration and biopsy, morphology and histochemical and enzymatic stains; and cytogenetic studies. A diagnosis of ALL required confirmation by morphology, negative peroxidase, and positive terminal deoxynucleotidyl transferase (TdT) and/or common acute lymphoblastic leukemia antigen (CALLA). Immunophenotyping and electron microscopic studies were confirmatory and were used in the diagnostic evaluation of difficult cases.
Therapy
Induction consisted of eight courses of alternating intensive chemotherapy. Courses 1, 3, 5 and 7 were 'hyper-CVAD', consisting of hyper-fractionated cyclophosphamide, 300 mg/m 2 i.v. over 2 h q 12 h for six doses, given on days 1-3; vincristine, 2 mg i.v., given on days 4 and 11; doxorubicin (adriamycin), 50 mg/m 2 i.v. over 2 h on day 4; and dexamethasone 40 mg per day, given either i.v. or orally on days 1-4 and 11-14. Courses 2, 4, 6, and 8 consisted of methotrexate, 1 g/m 2 i.v. over 24 h, given on day 1; and cytarabine, 3 g/m 2 over 2 h q 12 h for four doses, given on days 2 and 3. The dose of cytarabine was reduced to 1 g/m 2 for patients over the age of 60 years. Calcium leucovorin was given at a dose of 50 mg i.v. q 6 h, starting 12 h after the completion of the methotrexate, and continuing until the methotrexate blood levels were less than 0.1 M. G-CSF, 5 g/kg s.c. twice a day, was started 24 h after chemotherapy was completed and continued until the total white blood cell count was у30 000/l. Subsequent courses were begun when the total white blood cell count was greater than 20 000/l and the platelet count was greater than 60 000/l, or on day 21, whichever was earlier. We found that patients whose treatments were started when their white blood cell counts were this high had briefer total durations of neutropenia following chemotherapy. Main-tenance therapy was mercaptopurine 50 mg orally three times daily and methotrexate 20 mg/m 2 i.v. weekly.
Historical (high-dose Ara-C) control population
The results of this study were compared with those observed in 63 previously reported patients with refractory ALL treated on two sequential studies in the previous period (1985) (1986) (1987) (1988) (1989) (1990) (1991) who were treated with mitoxantrone, 5 mg/m 2 i.v. over 1 h daily for 5 days and cytosine arabinoside, 3 g/m 2 i.v. over 2 h every 12 h for six without (29 patients) or with (34 patients) GM-CSF, as previously reported. 9, 10 For the two groups in the high-dose Ara-C control population, there were no significant differences in pretreatment characteristics, except that the no GM-CSF group was significantly younger (24 vs 31 years; P = 0.04). Following treatment, days to recovery of granulocytes were longer (33 vs 25 days; P = 0.005) in the no GM-CSF group, and survival was shorter (29 vs 21 weeks; P = 0.05) in the no GM-CSF group. Entry criteria for both the current and the previous studies were the same. Patients in the high-dose Ara-C control group received similar supportive care therapy (platelets, red cells, antibiotic regimens) as the study population.
Response criteria
Bone marrow aspiration was performed at day 14 and day 21, or sooner if clinically appropriate. Complete remission (CR) was defined as 5% or fewer blasts in a normocellular or hypercellular bone marrow with normal peripheral and differential counts, including a granulocyte count greater than 1500/l and a platelet count greater than 100 000/l. Partial remission (PR) required similar criteria except for the presence of 6-25% marrow blasts. Patients failing induction therapy were categorized as: (1) early death if they expired within 2 weeks from the start of therapy; (2) death during induction if they expired 2 weeks or later while receiving induction therapy; or (3) resistant if they survived induction but regrew with resistant leukemia. Primary resistance was defined as persistence of a marrow leukemic infiltrate (MLI = marrow blast percent times cellularity) of 20% or more during therapy. Secondary resistance was defined as a reduction of the MLI to less than 20% with subsequent leukemia regrowth.
Statistical methods
The 2 test was used to compare differences among variables in the two groups. Survival after salvage therapy was measured from the date of start of treatment and CR duration was measured from the date of remission until documented relapse. Event-free survival was measured from the date of remission until either relapse or death in remission. Survival and remission duration curves were plotted by the method of Kaplan and Meier. 11 Differences among curves were compared by the modified Wilcoxon test 12 and by the log-rank test. 13 Patients who were subsequently transplanted were censored at the time of transplant. For the times to recovery of granulocytes and platelet counts, patients dying or changed to alternative therapy because of leukemic growth before attaining the desired counts were censored at the time of death or initiation of alternative therapy.
Results
The characteristics of the 66 patients entered on study and of the 63 patients in the historical (high-dose Ara-C) control group are detailed in Table 1 . Patients in the hyper-CVAD group had a higher median age of 32 as opposed to 27 in the high-dose Ara-C control group. There were more first salvage patients in the hyper-CVAD group than in the high-dose Ara-C control group, but other characteristics were similar between the two populations ( Table 1 ).
Responses
Overall, 29 patients (44%) achieved CR with the hyper-CVAD regimen, seven (11%) died during remission induction with hypoplastic marrows, and 30 (45%) had resistant disease. The CR rates were similar in the current study and in the highdose Ara-C control group (Table 2) . There were more patients having primary resistance to the hyper-CVAD regimen than in the high-dose Ara-C control group, but there was a trend toward more patients having secondary resistance to the highdose Ara-C control group.
Short-term survival was the same in both groups, but there was a significant difference in overall survival favoring hyper-CVAD which began to appear at about 18 weeks after treatment (P = 0.05; Figure 1 ). To test if there were imbalances in prognostic factors between the two groups, we first investigated whether any variable affected CR rate or survival in the combined study and historical groups and then checked whether that variable was similarly distributed in the two groups (Table 3) . Platelet count (P = 0.004), white blood cell count (P = 0.02), and lactic dehydrogenase (P = 0.038) were associated with significantly different CR rates, while there was a trend toward different CR rates based on hemoglobin (P = 0.051) and age (P = 0.054). All of these variables were equally distributed between the two groups ( Table 1) . Salvage attempt (P = 0.007), platelet count (P = 0.018), and hemoglobin (P = 0.026) were associated with significantly different survivals, and age (P = 0.06) showed a trend for survival. Again, all of these variables were equally distributed between the two groups except for first salvage status with significantly more first remission patients included in the current study (P = 0.016; Table 1 ). When only first salvage patients were evaluated, there was a significant difference between hyper-CVADtreated patients and the historical group which began to appear after about 12 weeks on therapy (P = 0.016; Figure 2 ). These differences could substantially be accounted for by the significant differences in disease-free survival in first salvage patients (52 vs 20 weeks; P = 0.008; Figure 3) .
Three patients were transplanted in remission following hyper-CVAD, and 12 patients were transplanted in relapse after hyper-CVAD. The survival of these 15 transplanted patients was virtually superimposable on the survival of the hyper-CVAD group as a whole.
Hematologic recovery after chemotherapy and myelosuppression-associated complications
Hematologic recovery was compared after the first course of therapy in both groups. Six patients in the hyper-CVAD group had neutrophil nadirs greater than 500/l after therapy, while none of the high-dose Ara-C control patients had nadirs greater than 500/l. Recovery of the granulocytic series was 
Figure 1
Kaplan-Meier plot displaying the probability of survival of relapsed acute lymphoblastic leukemia patients. (-) hyper-CVAD protocol; (----) historical control group treated with high-dose Ara-C and mitoxantrone ± GM-CSF.
significantly faster among patients treated with hyper-CVAD than the high-dose Ara-C control group, with the number of days to recovery of granulocytes above 500/l being 20 days, compared to 28 days in the high-dose Ara-C control group (P Ͻ 0.0001). When hyper-CVAD patients were compared only to the 34 high-dose Ara-C control patients who received GM-CSF, however, the number of days to recovery was 20 compared to 25 days in the high-dose Ara-C control group (P = 0.04; Figure 4 ). The number of days to recovery of platelets above 30 000/l was not significantly different in the two groups (P = 0.25; Figure 5 ).
Febrile episodes (temperature у38.3°C for at least 4 h) and documented infections during the first course occurred with about half the frequency in the hyper-CVAD-treated patients as compared to the high-dose Ara-C control group. This ratio remained even when the patients in the current study were compared to high-dose Ara-C control patients who were given GM-CSF to accelerate their leukocyte recovery. Table 4 lists the distribution of the most serious febrile events during chemotherapy. Unexpected non-hematologic toxicities were not seen.
Discussion
The treatment of ALL in adults has met with much less success than in children with the same disease over the past three decades and long-term disease-free survival is not possible in the majority of adult patients treated. [3] [4] [5] Because most adult patients will relapse after a relatively brief remission, more effective therapeutic approaches are needed. In a recent review by Welborn, 6 consisting of a compilation of 44 studies involving 861 patients and using a variety of reinduction treatment regimens for relapsed and refractory ALL, CR rates varied from 5 to 89% but median duration of CR was 6 months or less in all. Furthermore, the median duration of CR for the 44 studies was 3.8 ± 2.1 months. 6 Schiller et al 14 in a small group of adults with ALL who were refractory to treatment or in 
Figure 2
Kaplan-Meier plot displaying the probability of survival of first salvage acute lymphoblastic leukemia patients. (-) hyper-CVAD protocol; (----) historical group treated with high-dose Ara-C and mitoxantrone ± GM-CSF.
relapse, were able to induce CR in eight of 11 patients (73%) using a combination of etoposide, ifosfamide and mitoxantrone, but the median duration of the CR was three months. Liso et al, 15 using a treatment regimen of etoposide, cytarabine and mitoxantrone, achieved a CR rate in 10 of 20 patients (50%), but the median duration of remission was only 5 months. Freund et al, 16 using vincristine, daunorubicin, asparaginase and prednisone followed by 6-mercaptopurine, cytarabine and cyclophosphamide, achieved a CR in 41/66 (60%), with a median disease-free survival after treatment for first relapse of 2.9 months and an overall survival after treatment for first relapse of 6.6 months. Mazza et al 17 were unable to detect any advantage for first salvage status in their patients given mitoxantrone, etoposide and high-dose cytarabine. These studies were similar to regimens used in relapsed ALL previously reported from our institution. [18] [19] [20] [21] In the current study, 66 adults with refractory ALL received the hyper-CVAD regimen, an intensive regimen consisting of eight courses of alternating high-dose chemotherapy with Kaplan-Meier plot displaying the probability of eventfree survival of first salvage acute lymphoblastic leukemia patients following complete remission. (-) hyper-CVAD protocol; (----) historical group treated with high-dose Ara-C and mitoxantrone ± GM-CSF. growth factor support followed by oral maintenance treatment. The results were compared with those of a historical (high-dose Ara-C) control group of patients who received intensive chemotherapy with or without growth factor support. Patients treated on the hyper-CVAD regimen showed a similar CR rate to patients in the high-dose Ara-C control group. The patients on the current study and patients in the high-dose Ara-C control group also had similar short-term (first 18 weeks) survival rates. Nevertheless, patients treated on the current study had a significantly improved long-term survival rate. The improvement in long-term survival primarily accrued in patients who were being treated for first salvage, and was especially notable in differences in disease-free survival for first salvage patients who entered complete remission on the hyper-CVAD regimen.
The improved results reported in the current study were not necessarily a consequence of more intensive therapy. Many reported studies which have high CR rates also report short remission duration.
14 Furthermore, the duration of neutropenia Ͻ500 granulocytes/l was shorter by 5 days in the cur-
Figure 4
Kaplan-Meier plot displaying the probability of granulocyte recovery above 500 cells/l. (-) hyper-CVAD group; historical high-dose Ara-C and mitoxantrone groups treated with (----) or without (......) GM-CSF.
Table 4
Incidence of febrile episodes and documented infections during the first course of chemotherapy in patients treated with hyper-CVAD, in the high-dose Ara-C control group, or in the subset of the high-dose Ara-C control group treated with GM-CSF
Episode
No. of patients (%) Study High-dose High-dose population Ara-C control Ara-C control (n = 66) (n = 63) with GM-CSF (n = 34) (6) rent regimen that a comparable population given a high-dose cytarabine-based regimen with growth factor support. This indicates that the current regimen was not more intensely myeloablative. The significantly lower incidence of serious infections was gratifying, but did not significantly affect the overall CR rate.
In the present study, we were able to show that the hyper-CVAD protocol had a significant impact on survival. The patients who clearly benefitted were the individuals who were being treated for their first relapse of ALL who entered remission on their first course of this regimen. We would suggest that the hyper-CVAD regimen is more effective that highdose Ara-C-containing regimens because it is more selective for leukemic lymphoblasts and less toxic. This does not rule out the possibility that high-dose Ara-C-containing regimens are better for certain small subgroups of acute lymphoblastic leukemia patients that could not be further dissected from our treatment cohort because of its size. We are currently evaluating this regimen in front-line ALL patients where we expect the impact of this regimen to be greatest.
